ReviewNature immunology2022
A global effort to dissect the human genetic basis of resistance to SARS-CoV-2 infection.
Review in Nature immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 69 citations in OpenAlex.
- Identification of Contacts With High Rates of Missed and Asymptomatic Infection Following an Outbreak of Ebola Virus Disease: A Seroepidemiological Study in Likati Health Zone, Democratic Republic of the Congo.Open forum infectious diseases · 2026Article
- Toward a monogenic architecture of human infections: From 1996 to 2026.Journal of human immunity · 2026Review
- From HIV to SARS-CoV-2 associated neurological disorder ("HAND" to "SAND"): Viral infection as a "time-bomb" for the aging brain.Neuroscience applied · 2026Review
- The seven enigmas of SARS-CoV-2: from the past to the future.Journal of human immunity · 2025Article
- Article
- Role of ACE1, ACE2, and CCR5-Δ32 Polymorphisms in the Transmission of SARS-CoV-2 to Intimate Contacts.Biology · 2025Article
- Genetic diversity of the immunoglobulin heavy chain locus in cohorts of patients affected with SARS-CoV-2.Human genomics · 2025Article
- Biological characteristics of SARS-CoV-2 resistant populations by integrated gut microbiota sequencing, metabolomics, and proteomics: a cohort comparison study.Frontiers in medicine · 2025Article
- Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice.Nature communications · 2024Article
- Inference of Host-Pathogen Interaction Matrices from Genome-Wide Polymorphism Data.Molecular biology and evolution · 2024Article
- Circulating inflammatory cytokines and the risk of sepsis: a bidirectional mendelian randomization analysis.BMC infectious diseases · 2024Article
- Review
- Diversity in the Clinical Course and Outcome of COVID-19 in Patients with Different Inborn Errors of Immunity can be Associated with the Type of Error.Advanced biomedical research · 2024Article
- Potential protective role of interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) in COVID-19.Frontiers in cellular and infection microbiology · 2024Article
- Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.Research square · 2023Article
- Bacterial Proteases as Potentially Exploitable Modulators of SARS-CoV-2 Infection: Logic from the Literature, Informatics, and Inspiration from the Dog.Biotech (Basel (Switzerland)) · 2023Article
- A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals.iScience · 2023Article
- Human Genomics of COVID-19 Pneumonia: Contributions of Rare and Common Variants.Annual review of biomedical data science · 2023Review
- Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease.The Journal of biological chemistry · 2023Review
- Exploring the Immunomodulatory Properties of Stem Cells in Combating COVID-19: Can We Expect More?Bioengineering (Basel, Switzerland) · 2023Article
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
16 authors at 20 institutions in 27 countries.
Funding
Abstract
SARS-CoV-2 infections display tremendous interindividual variability, ranging from asymptomatic infections to life-threatening disease. Inborn errors of, and autoantibodies directed against, type I interferons (IFNs) account for about 20% of critical COVID-19 cases among SARS-CoV-2-infected individuals. By contrast, the genetic and immunological determinants of resistance to infection per se remain unknown. Following the discovery that autosomal recessive deficiency in the DARC chemokine receptor confers resistance to Plasmodium vivax, autosomal recessive deficiencies of chemokine receptor 5 (CCR5) and the enzyme FUT2 were shown to underlie resistance to HIV-1 and noroviruses, respectively. Along the same lines, we propose a strategy for identifying, recruiting, and genetically analyzing individuals who are naturally resistant to SARS-CoV-2 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.